NCT03104673 (MSP_Ext) is a clinical trial in Preterm Birth, sponsored by University of Oxford.

Who is sponsoring NCT03104673?

NCT03104673 is sponsored by University of Oxford.

What condition does NCT03104673 study?

NCT03104673 studies Preterm Birth.

Is NCT03104673 still recruiting?

NCT03104673 is currently completed. Last updated 21 June 2021.

Last reviewed 2021-06-21 · How we verify

NCT03104673: MSP_Ext

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molecular Signature Children

Completed Last updated 21 June 2021

What this trial tests

trial in Preterm Birth in 384 participants. Completed in 28 January 2021.

Timeline

30 April 2017

Primary endpoint
28 January 2021

28 January 2021

Quick facts

Lead sponsor	University of Oxford
Status	Completed
Study type	OBSERVATIONAL
Enrollment	384
Start date	30 April 2017
Primary completion	28 January 2021
Estimated completion	28 January 2021
Sites	1 location across Thailand

Conditions studied

Preterm Birth — all drugs for Preterm Birth →

Sponsor

University of Oxford

Who can join

Eligibility, any sex, with Preterm Birth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preterm birth (PTB) occurs before 37 weeks of gestation and is a major cause of neonatal mortality and morbidity. PTB results from heterogeneous influences. One of them is the inherited predisposition of spontaneous PTB, and another is the change in the placental microbial composition as this can cause infections, which lead to inflammation, a common cause of preterm birth. Interestingly, maternal periodontal disease is an independent risk factor for PTB, low birth weight and fetal growth restriction. Immune responses to infectious events or inflammation as well as genetic predisposition to inherited conditions have successfully been studied by using assessing genetic expression profiling. The molecular signature is sets of genes, proteins, genetic variants or other variables that can be used as markers for a particular phenotype. Child morbidity from malnutrition resulting in poor growth and stunting remains a major public health issue that affects the local population just like PTB. While risk factors for malnutrition are multifaceted, there is also a hypothesized causal link between early gut microbiome disruption that leads to chronic malnutrition in otherwise healthy infants. Molecular signatures including the intestinal microbiome development of preterm infants will be evaluated and compared to the term (≥37 weeks' gestation) counterparts. Moreover, a comprehensive examination of possible factors associated with poor growth and poor motor- and neurodevelopment will be assessed. In this extension study: The primary goal for the child is to evaluate the perturbation in the development of the genomic profile including intestinal microbial habitat from children in a rural and limited-resource setting from birth to two years of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Preterm Birth

Currently open trials in the same condition.

NCT07265583 — Early Prediction of Lung Injury in Preterm Infants Score · recruiting
NCT07305935 — Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury · NA · recruiting
NCT07192393 — Health-Related Quality-of-Life and Household Financial and Wellbeing Impacts of Prematurity and Necrotising Enterocoliti · recruiting
NCT06826859 — Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH) · Phase 1, PHASE2 · recruiting
NCT07231432 — Promoting Kangaroo Care for Preterm or Low Birthweight Infants in Rural India · NA · active not recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03104673 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 21 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03104673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing